Ask AI
Bill106th CongressFiled Jul 29, 1999Health
H.R. 2634

Drug Addiction Treatment Act of 2000

Bill journey · stage 2 of 5

Under committee review

Filed
Comm.
Floor
Both
Law

What it doesSummary passed house amended (Jul 19, 2000)

Drug Addiction Treatment Act of 2000 - Amends the Controlled Substances Act to waive the requirement that practitioners who dispense narcotic drugs to individuals for maintenance or detoxification treatment annually obtain a separate registration for that purpose, and that the Attorney General register an applicant to dispense narcotic drugs to individuals for such treatment, in the case of the dispensing by a practitioner of narcotic drugs in schedule III, IV, or V or combinations of such drugs (schedule III-V drugs) if the practitioner and the drugs meet specified conditions. Limits the total number of patients of either a sole practitioner or of a group to 30 patients at any one time. Authorizes the Secretary of Health and Human Services to set different numerical ceilings according to the number of practitioners in the group practice.

Requires that: (1) the practitioner, before dispensing schedule III-V drugs to patients for maintenance or detoxification treatment, submit to the Secretary a notification of intent to begin dispensing such drugs for that purpose, including certifications that the practitioner is a "qualifying physician" (defined to mean a physician who is licensed under State law and meets specified training and experience requirements), and has the capacity to refer the patients for appropriate counseling and other appropriate ancillary; and (2) the schedule III-V drugs have been approved for use in maintenance or detoxification treatment and have not been the subject of an "adverse determination" (i.e., requires additional standards regarding the qualifications of practitioners to provide such treatment, or requires standards regarding the quantities of the drugs that may be provided for unsupervised use).

Sets forth specified procedural requirements to make the waiver effective. Directs the Attorney General, upon receiving a notification under this Act, to assign the practitioner involved an identification number for inclusion with the registration issued for the practitioner. Requires that the identification number be appropriate to preserve the confidentiality of patients for whom the practitioner has dispensed narcotic drugs under the waiver. Directs: (1) the Secretary, within 45 days after receiving a notification, to make a determination of whether the practitioner involved meets all waiver requirements; and (2) the Attorney General, if the Secretary fails to make such determination by the end of such period, to assign the physician an identification number.

Requires the Secretary, in consultation with the Administrator of the Drug Enforcement Administration, the Administrator of the Substance Abuse and Mental Health Services Administration, the Director of the Center for Substance Abuse Treatment, the Director of the National Institute on Drug Abuse, and the Commissioner of Food and Drugs (consulted parties), to issue regulations or practice guidelines to address: (1) approval of additional credentialing bodies and their responsibilities; and (2) additional exemptions. Specifies that nothing in such regulations or guidelines may authorize any Federal official or employee to exercise supervision or control over the practice of medicine or the manner in which medical services are provided.

Directs the Secretary: (1) to issue a treatment improvement protocol containing best practice guidelines for the treatment and maintenance of opiate-dependent patients; and (2) to develop the protocol in consultation with the consulted parties and other substance abuse disorder professionals, with the protocol guided by science.

Prohibits a State, for three years, from precluding a practitioner from dispensing or prescribing drugs in schedule III-V to patients for maintenance of detoxification treatment unless the State enacts a law prohibiting a practitioner from dispensing such drugs.

Authorizes the Secretary and the Attorney General, for three years, to make determinations regarding whether: (1) treatments provided under such waivers have been effective forms of maintenance and detoxification treatment in clinical settings; (2) such waivers have significantly increased the availability of such treatment; and (3) such waivers have adverse public health consequences. Authorizes the Secretary or the Attorney General, after consulting each other, to terminate the waiver mechanism after announcing their decision in the Federal Register. Authorizes appropriations to assist the Secretary with the additional duties established for the Secretary pursuant to this Act.

What just happenedJul 27, 2000

Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 740.

Who’s behind it

Rep. Bliley, Tom [R-VA-7](R-VA)Sponsor
10 cosponsors3 D7 R
Read on Congress.gov
10cosponsors2committees28actions2related bills
  1. Jul 27, 2000Calendars

    Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 740.

  2. Jul 19, 2000FloorH38800

    The title of the measure was amended. Agreed to without objection. (text: CR 7/27/2000 H7200)

  3. Jul 19, 2000FloorH38310

    Motion to reconsider laid on the table Agreed to without objection.

  4. Jul 19, 2000FloorH37300

    On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 412 - 1 (Roll no. 416).

  5. Jul 19, 2000Floor8000

    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 412 - 1 (Roll no. 416).

  6. Jul 19, 2000FloorH30000

    Considered as unfinished business. (consideration: CR H6564)

  7. Jul 18, 2000FloorH37220

    At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.

  8. Jul 18, 2000FloorH8D000

    DEBATE - The House proceeded with forty minutes of debate on H.R. 2634.

  9. Jul 18, 2000FloorH30000

    Considered under suspension of the rules. (consideration: CR H6374-6377; text: CR H6374-6375)

  10. Jul 18, 2000FloorH30300

    Mr. Bliley moved to suspend the rules and pass the bill, as amended.

  11. Nov 3, 1999CalendarsH12410

    Placed on the Union Calendar, Calendar No. 255.

  12. Nov 3, 1999DischargeH12300

    Committee on Judiciary discharged.

    Judiciary Committee
  13. Nov 3, 1999Committee5500

    Committee on Judiciary discharged.

    Judiciary Committee
  14. Nov 3, 1999IntroReferralH11210

    House Committee on Judiciary Granted an extension for further consideration ending not later than Nov. 3, 1999.

    Judiciary Committee
  15. Nov 3, 1999CommitteeH12200

    Reported (Amended) by the Committee on Commerce. H. Rept. 106-441, Part I.

    Energy and Commerce Committee
  16. Nov 3, 1999Committee5000

    Reported (Amended) by the Committee on Commerce. H. Rept. 106-441, Part I.

    Energy and Commerce Committee
  17. Oct 13, 1999CommitteeH19000

    Ordered to be Reported (Amended) by Voice Vote.

    Energy and Commerce Committee
  18. Oct 13, 1999CommitteeH15000-B

    Committee Consideration and Mark-up Session Held.

    Energy and Commerce Committee
  19. Sep 30, 1999CommitteeH23000

    Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote.

    Health and Environment Subcommittee
  20. Sep 30, 1999CommitteeH22000

    Subcommittee Consideration and Mark-up Session Held.

    Health and Environment Subcommittee
  21. Aug 6, 1999CommitteeH11000

    Referred to the Subcommittee on Crime.

    Crime and Federal Government Surveillance Subcommittee
  22. Jul 30, 1999CommitteeH21000

    Subcommittee Hearings Held.

    Health and Environment Subcommittee
  23. Jul 29, 1999CommitteeH11000

    Referred to the Subcommittee on Health and Environment.

    Health and Environment Subcommittee
  24. Jul 29, 1999IntroReferralH11100

    Referred to the Committee on Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Judiciary Committee
  25. Jul 29, 1999IntroReferralH11100-A

    Referred to the Committee on Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  26. Jul 29, 1999IntroReferralH11100

    Referred to the Committee on Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Energy and Commerce Committee
  27. Jul 29, 1999IntroReferralIntro-H

    Introduced in House

  28. Jul 29, 1999IntroReferral1000

    Introduced in House

Passed House amendedJul 19, 200036
Drug Addiction Treatment Act of 2000 - Amends the Controlled Substances Act to waive the requirement that practitioners who dispense narcotic drugs to individuals for maintenance or detoxification treatment annually obtain a separate registration for that purpose, and that the Attorney General register an applicant to dispense narcotic drugs to individuals for such treatment, in the case of the dispensing by a practitioner of narcotic drugs in schedule III, IV, or V or combinations of such drugs (schedule III-V drugs) if the practitioner and the drugs meet specified conditions. Limits the total number of patients of either a sole practitioner or of a group to 30 patients at any one time. Authorizes the Secretary of Health and Human Services to set different numerical ceilings according to the number of practitioners in the group practice.

Requires that: (1) the practitioner, before dispensing schedule III-V drugs to patients for maintenance or detoxification treatment, submit to the Secretary a notification of intent to begin dispensing such drugs for that purpose, including certifications that the practitioner is a "qualifying physician" (defined to mean a physician who is licensed under State law and meets specified training and experience requirements), and has the capacity to refer the patients for appropriate counseling and other appropriate ancillary; and (2) the schedule III-V drugs have been approved for use in maintenance or detoxification treatment and have not been the subject of an "adverse determination" (i.e., requires additional standards regarding the qualifications of practitioners to provide such treatment, or requires standards regarding the quantities of the drugs that may be provided for unsupervised use).

Sets forth specified procedural requirements to make the waiver effective. Directs the Attorney General, upon receiving a notification under this Act, to assign the practitioner involved an identification number for inclusion with the registration issued for the practitioner. Requires that the identification number be appropriate to preserve the confidentiality of patients for whom the practitioner has dispensed narcotic drugs under the waiver. Directs: (1) the Secretary, within 45 days after receiving a notification, to make a determination of whether the practitioner involved meets all waiver requirements; and (2) the Attorney General, if the Secretary fails to make such determination by the end of such period, to assign the physician an identification number.

Requires the Secretary, in consultation with the Administrator of the Drug Enforcement Administration, the Administrator of the Substance Abuse and Mental Health Services Administration, the Director of the Center for Substance Abuse Treatment, the Director of the National Institute on Drug Abuse, and the Commissioner of Food and Drugs (consulted parties), to issue regulations or practice guidelines to address: (1) approval of additional credentialing bodies and their responsibilities; and (2) additional exemptions. Specifies that nothing in such regulations or guidelines may authorize any Federal official or employee to exercise supervision or control over the practice of medicine or the manner in which medical services are provided.

Directs the Secretary: (1) to issue a treatment improvement protocol containing best practice guidelines for the treatment and maintenance of opiate-dependent patients; and (2) to develop the protocol in consultation with the consulted parties and other substance abuse disorder professionals, with the protocol guided by science.

Prohibits a State, for three years, from precluding a practitioner from dispensing or prescribing drugs in schedule III-V to patients for maintenance of detoxification treatment unless the State enacts a law prohibiting a practitioner from dispensing such drugs.

Authorizes the Secretary and the Attorney General, for three years, to make determinations regarding whether: (1) treatments provided under such waivers have been effective forms of maintenance and detoxification treatment in clinical settings; (2) such waivers have significantly increased the availability of such treatment; and (3) such waivers have adverse public health consequences. Authorizes the Secretary or the Attorney General, after consulting each other, to terminate the waiver mechanism after announcing their decision in the Federal Register. Authorizes appropriations to assist the Secretary with the additional duties established for the Secretary pursuant to this Act.

Reported to House amended, Part INov 3, 199918
Drug Addiction Treatment Act of 1999 - Amends the Controlled Substances Act to waive the requirement that practitioners who dispense narcotic drugs to individuals for maintenance or detoxification treatment annually obtain a separate registration for that purpose, and that the Attorney General register an applicant to dispense narcotic drugs to individuals for such treatment, in the case of the dispensing by a practitioner of narcotic drugs in schedule IV or V or combinations of such drugs (schedule IV-V drugs) if the practitioner and the drugs meet specified conditions. Limits the total number of patients of either a sole practitioner or of a group to 40 patients at any one time. Authorizes the Secretary of Health and Human Services to set different numerical ceilings according to the number of practitioners in the group practice.

Requires that: (1) the practitioner, before dispensing schedule IV-V drugs to patients for maintenance or detoxification treatment, submit to the Secretary a notification of intent to begin dispensing such drugs for that purpose, including certifications that the practitioner is a "qualifying physician" (defined to mean a physician who is licensed under State law and meets specified training and experience requirements), and has the capacity to refer the patients for appropriate counseling and other appropriate ancillary; and (2) the schedule IV-V drugs have been approved for use in maintenance or detoxification treatment and have not been the subject of an "adverse determination" (i.e., requires additional standards regarding the qualifications of practitioners to provide such treatment, or requires standards regarding the quantities of the drugs that may be provided for unsupervised use).

Sets forth specified procedural requirements to make the waiver effective. Directs the Secretary to assign a unique identifier to each notification of the intent of a practitioner to dispense schedule IV-V drugs to patients for maintenance or detoxification treatment, and to provide to the Attorney General all information contained in such notifications.

Authorizes the Secretary and the Attorney General, during the three-year period beginning on the date of this Act's enactment, to make determinations regarding whether: (1) treatments provided under such waivers have been effective forms of maintenance and detoxification treatment in clinical settings; (2) such waivers have significantly increased the availability of such treatment; and (3) such waivers have adverse public health consequences. Authorizes the Secretary or the Attorney General, after consulting each other, to terminate the waiver mechanism after announcing their decision in the Federal Register. Authorizes appropriations to assist the Secretary with the additional duties established for the Secretary pursuant to this Act.

Introduced in HouseJul 29, 199900

Drug Addiction Treatment Act of 1999 - Amends the Controlled Substances Act to waive the requirement that practitioners who dispense narcotic drugs to individuals for maintenance or detoxification treatment annually obtain a separate registration for that purpose, and that the Attorney General register an applicant to dispense narcotic drugs to individuals for such treatment, in the case of the dispensing by a practitioner of narcotic drugs in schedule IV or V or combinations of such drugs (schedule IV-V drugs) if the practitioner and the drugs meet specified conditions. Requires that: (1) the practitioner, before dispensing schedule IV-V drugs to patients for maintenance or detoxification treatment, submit to the Secretary of Health and Human Services a notification of intent to begin dispensing such drugs for that purpose, including certifications that the practitioner is licensed under State law and has the ability to treat and manage opiate-dependent patients, has the capacity to refer the patients for appropriate counseling and other appropriate ancillary services, and meets other specified requirements; and (2) the schedule IV-V drugs have been approved for use in maintenance or detoxification treatment and have not been the subject of an "adverse determination" (i.e., requires additional standards regarding the qualifications of practitioners to provide such treatment, or requires standards regarding the quantities of the drugs that may be provided for unsupervised use).

Sets forth specified procedural requirements to make the waiver effective.

Authorizes the Secretary and the Attorney General, during the three-year period beginning on the date of this Act's enactment, to make determinations regarding whether: (1) treatments provided under such waivers have been effective forms of maintenance and detoxification treatment in clinical settings; (2) such waivers have significantly increased the availability of such treatment; and (3) such waivers have adverse public health consequences. Authorizes the Secretary to collect data from the practitioners for whom waivers are in effect. Sets forth further requirements with respect to the Secretary and the Attorney General, and further procedural requirements.

Drug Addiction Treatment Act of 2000 — Informed